Endocrinology Search
Endocrinology Endocrinology
hyperprolactinemia
HYPERPROLACTINEMIA
Hyperprolactinemia is the presence of elevated prolactin levels that occurs in about one-thirds of patients w/ chronic kidney disease & resolves after successful transplantation.
It may cause visual field defects or headache in both men and women.
In women, signs and symptoms include menstrual irregularity, galactorrhea, infertility, vaginal dryness, dyspareunia, loss of libido and reduction in vertebral bone density (in sustained, pronounced hyperprolactinemia).
While in men, signs and symptoms include diminished libido, hypogonadism, gonadotrophin suppression, osteopenia, decreased muscle mass, and decreased facial hair that may occur in prolonged hyperprolactinemia.

Hyperprolactinemia Diagnosis

Evaluation

  • Physiologic causes, renal failure, parasellar tumors, hypothyroidism and drug-induced hyperprolactinemia should be ruled out before extensive evaluation

Measure Fasting Prolactin (PRL) Level

  • Normal range: <30 ng/mL normal fasting prolactin (PRL) level
  • Diagnostic range: >250 ng/mL (with physiologic causes and drug-induced causes ruled out) usually indicates prolactinoma
    • A prolactinoma is less likely with prolactin (PRL) level <100 ng/mL
    • Several measurements should be made to confirm diagnosis

Radiologic Evaluation

  • Should be performed if there is no obvious cause of hyperprolactinemia and if tumor is suspected
    • Physician must decide whether a radiographic study is warranted if prolactin (PRL) level <250 ng/mL but >100 ng/mL
  • Magnetic resonance imaging (MRI) with gadolinium enhancement is the imaging study of choice
    • Computed tomography (CT) with contrast may also be used
    • Serum prolactin (PRL) >200 ng/mL indicates prolactinoma
      • Prolactinomas are classified as macroadenoma if the size is ≥10 mm; microadenoma if <10 mm in size
    • Serum prolactin (PRL) <200 ng/mL with large pituitary mass usually indicates hyperprolactinemia secondary to stalk compression
    • Magnetic resonance imaging (MRI) and computed tomography (CT) scan normal and no obvious cause, patient is said to have idiopathic hyperprolactinemia

Laboratory Tests

  • To establish the diagnosis of hyperprolactinemia, it is recommended to have a single measurement of serum prolactin
    • A level above the upper limits confirms the diagnosis
  • Careful history and physical exam including cranial nerve examination
    • Check for galactorrhea, visual field defects, signs of cirrhosis, hair growth pattern on the body, etc
    • Drug history
  • Blood chemistry [blood urea nitrogen (BUN), creatinine]
  • Other pituitary hormones (eg testosterone levels, cortisol, insulin growth factor-1) as necessary
  • Pregnancy test
  • To rule out macroprolactinemia, polyethylene glycol precipitation is recommended
  • Thyroid function tests (to rule out hypothyroidism)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
DAPA-CKD heralds a new era for dapagliflozin in kidney disease
Pearl Toh, 6 days ago
Adding dapagliflozin to standard of care (SOC) significantly reduces the risk of worsening kidney function, death due to kidney or cardiovascular (CV) disease, and all-cause mortality compared with SOC alone in patients with chronic kidney disease (CKD), regardless of whether they have type 2 diabetes (T2D), reveals the DAPA-CKD* trial — showing dapagliflozin charting new territories from diabetes to the renal realm.
Empagliflozin reduces CV death, HF hospitalization in HFrEF patients
Roshini Claire Anthony, 6 days ago

In patients with chronic heart failure with reduced ejection fraction (HFrEF), empagliflozin reduced the risk of cardiovascular (CV) death or heart failure hospitalization (HHF) and decline in estimated glomerular filtration rate (eGFR), results of the EMPEROR-Reduced* trial showed.